Dopamine dysregulation syndrome in Parkinson's disease

Curr Opin Neurol. 2004 Aug;17(4):393-8. doi: 10.1097/01.wco.0000137528.23126.41.


Purpose of review: Dopamine replacement therapy in Parkinson's disease ameliorates motor symptoms. However, it has recently been recognized that a small sub-group of patients suffer motor and behavioural disturbances attributable to taking quantities of medication well beyond the dose required to treat their motor disabilities. This review examines the phenomenology of dopamine dysregulation syndrome in relation to the current understanding of basal ganglia function and its impact on long-term management.

Recent findings: Cortico-striato-thalamic circuits are implicated in the behavioural and motor disturbances associated with compulsive medication use in Parkinson's disease. Advances in understanding of the role of dopamine in psychostimulant addiction are important in helping to understand dopamine dysregulation.

Summary: Recognition of dopamine dysregulation syndrome and characterization of its phenomenology supports the notion that the medication used to treat Parkinson's disease can disrupt basal ganglia mediated motor and behavioural functioning. Refinement of clinical strategies to predict, identify and manage this syndrome will aid the future treatment of motor and non-motor complications of Parkinson's disease.

Publication types

  • Review

MeSH terms

  • Animals
  • Antiparkinson Agents / adverse effects*
  • Basal Ganglia / drug effects
  • Basal Ganglia / metabolism
  • Basal Ganglia / physiopathology
  • Dopamine / metabolism*
  • Dopamine Agonists / adverse effects*
  • Humans
  • Mental Disorders / chemically induced*
  • Mental Disorders / metabolism
  • Mental Disorders / physiopathology
  • Parkinson Disease / drug therapy
  • Reward
  • Substance-Related Disorders / metabolism
  • Substance-Related Disorders / physiopathology*
  • Ventral Tegmental Area / drug effects*
  • Ventral Tegmental Area / metabolism
  • Ventral Tegmental Area / physiopathology


  • Antiparkinson Agents
  • Dopamine Agonists
  • Dopamine